<p>REGENXBIO（纳斯达克代码：RGNX - 获取免费报告）在周五发布的报告中，摩根大通的股票分析师将其目标价格从 25.00 美元下调至 14.00 美元，Benzinga 报道。该公司目前对这家生物技术公司的股票给予 “买入” 评级。摩根大通的目标价格暗示该公司当前价格有 139.93% 的潜在上涨空间。</p>
<p>其他几家券商也对 RGNX 发布了报告。Chardan Capital 在 2 月 10 日的研究报告中将 REGENXBIO 的目标价格从 52.00 美元下调至 50.00 美元，并给予该公司 “买入” 评级。Robert W. Baird 在 2 月 10 日的研究报告中设定了 REGENXBIO 的目标价格为 27.00 美元。Weiss Ratings 在 1 月 22 日的研究报告中重新发布了对 REGENXBIO 的 “卖出（d-）” 评级。Wall Street Zen 在 1 月 31 日的研究报告中将 REGENXBIO 的评级从 “持有” 下调至 “卖出”。最后，摩根士丹利在周五的研究报告中设定了 REGENXBIO 的目标价格为 16.00 美元。九位分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，REGENXBIO 的平均评级为 “适度买入”，共识目标价格为 23.91 美元。</p>
<p><strong>阅读我们关于 REGENXBIO 的最新股票分析</strong></p>
<h2>REGENXBIO 股票下跌 6.5%</h2>
<p>在周五的午盘交易中，纳斯达克：RGNX 下跌 0.41 美元，报 5.84 美元。该公司的交易量为 2,810,619 股，而其平均交易量为 1,031,145 股。REGENXBIO 的 52 周低点为 5.79 美元，52 周高点为 16.19 美元。该股票的 50 日移动平均价格为 8.92 美元，200 日移动平均价格为 11.03 美元。该公司的市值为 3.012 亿美金，市盈率为-1.55，贝塔值为 1.12。</p>
<p>REGENXBIO（纳斯达克代码：RGNX - 获取免费报告）最后一次公布财报是在 5 月 14 日，生物技术公司报告每股收益（EPS）为-1.72 美元，低于市场共识预期的 0.10 美元，差距为-1.82 美元。REGENXBIO 的股本回报率为-103.12%，净利润率为-113.75%。该公司在本季度的收入为 639 万美元，而分析师的预期为 2584 万美元。作为一个整体，研究分析师预测 REGENXBIO 在本年度的每股收益将为-2.88 美元。</p>
<h2>内部人士下注</h2>
<p>在其他新闻中，内部人士 Steve Pakola 在 5 月 11 日的交易中出售了 15,309 股公司的股票。股票以平均价格 11.02 美元出售，总交易额为 168,705.18 美元。交易完成后，该内部人士直接持有 232,617 股公司的股票，价值约为 2,563,439.34 美元。这代表了他们持股比例的 6.17% 的减少。该出售在向 SEC 的法律文件中披露，文件可以通过此链接访问。14.22% 的股票由公司内部人士持有。</p>
<h2>对 REGENXBIO 的对冲基金看法</h2>
<p>最近几家对冲基金和其他机构投资者修改了对 RGNX 的持股。AQR Capital Management LLC 在第一季度将其在 REGENXBIO 的股份增加了 2,247.7%。AQR Capital Management LLC 现在拥有 620,595 股生物技术公司的股票，价值 4,437,000 美元，此前在上个季度增持了 594,161 股。Assenagon Asset Management S.A.在第四季度将其在 REGENXBIO 的股份增加了 64.5%。Assenagon Asset Management S.A.现在拥有 1,160,380 股生物技术公司的股票，价值 16,709,000 美元，此前在上个季度增持了 454,977 股。Invenomic Capital Management LP 在第三季度购买了 REGENXBIO 的新头寸，价值约为 4,120,000 美元。Integral Health Asset Management LLC 在第三季度将其在 REGENXBIO 的股份增加了 57.1%。Integral Health Asset Management LLC 现在拥有 1,100,000 股生物技术公司的股票，价值 10,615,000 美元，此前在上个季度增持了 400,000 股。最后，State Street Corp 在第四季度将其在 REGENXBIO 的股份增加了 15.2%。State Street Corp 现在拥有 2,286,736 股生物技术公司的股票，价值 32,929,000 美元，此前在上个季度增持了 301,858 股。88.08% 的股票由机构投资者持有。</p>
<h2>REGENXBIO 新闻汇总</h2>
<p>以下是本周影响 REGENXBIO 的主要新闻故事：</p>
<ul>
<li>积极情绪：REGENXBIO 报告了其关键的 AFFINITY DUCHENNE 研究 RGX-202 的积极顶线结果，称主要终点以高统计显著性达成，且微型肌营养不良蛋白表达与功能改善相关，这支持了该项目的发展路径和潜在的加速审批。文章标题</li>
<li>积极情绪：管理层还强调了其他管道催化剂，包括 ABBV-RGX-314 在糖尿病视网膜病变方面的进展，预计将在第二季度进行给药，以及其他晚期结果将在 2026 年晚些时候公布，如果执行保持在轨道上，可能会创造未来的上行空间。文章标题</li>
<li>中性情绪：公司的财报电话会议及相关报道集中在临床更新和更广泛的管道战略上，投资者在分析新的试验数据是否能转化为商业机会。文章标题</li>
<li>消极情绪：第一季度的结果远低于预期：REGENXBIO 报告每股损失高达 1.72 美元，收入为 639 万美元，而共识接近 2584 万美元，这加剧了对公司财务持续性和持续亏损的担忧。文章标题</li>
<li>消极情绪：市场评论还指出现金担忧和季度亏损规模是导致股票下跌的原因，表明令人鼓舞的杜氏肌营养不良数据不足以抵消资产负债表的担忧。文章标题</li>
<li>消极情绪：Steve Pakola 的内部出售增加了一小部分消极情绪，尽管这比试验和财报消息的重要性要低。文章标题</li>
</ul>
<h2>关于 REGENXBIO</h2>
<p>(获取免费报告)</p>
<p>REGENXBIO Inc 是一家临床阶段的生物技术公司，专注于利用其专有的 NAV® AAV（腺病毒相关病毒）平台开发基因疗法。该公司设计了下一代 AAV 载体，旨在将功能基因传递到目标细胞，旨在解决一系列罕见遗传疾病以及眼科、代谢和神经系统疾病。REGENXBIO 的管道中有多个产品候选者处于不同的临床前和临床开发阶段，包括用于湿性年龄相关性黄斑变性（AMD）的 RGX-314、用于粘多糖贮积症 II 型（亨特综合症）的 RGX-121 以及用于其他罕见溶酶体贮积疾病的 RGX-121。</p>
<p>除了内部资助的项目外，REGENXBIO 还与主要生物制药公司建立了合作伙伴关系，以推进其 NAV 技术。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 REGENXBIO</li>
<li>Viking 股价创历史新高——基本面信号显示未来还有更多</li>
<li>Datavalut 获得关注：现在卖出的五个理由</li>
<li>TMC 股票：为什么这家未盈利的矿业公司值得关注</li>
<li>电网正在衰退——是时候购买其替代品了吗？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkdOWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkdOWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 REGENXBIO 吗？</h2>
<p>在你考虑 REGENXBIO 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 REGENXBIO 并不在名单上。</p>
<p>虽然 REGENXBIO 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

RGNX

标普生物技术 3 倍做多 - Direxion

纽交所高增长板生物技术指数 ETF - First Trust

<p>美国银行已将 REGENXBIO（NASDAQ:RGNX）的目标股价从 25.00 美元下调至 14.00 美元，同时维持 “买入” 评级。新的目标价暗示潜在上涨空间为 139.93%。其他分析师也调整了他们的评级，市场共识目标价为 23.91 美元。REGENXBIO 的股票目前交易价格为 5.84 美元，下跌 6.5%，市值为 3.012 亿美金。该公司在最近的财报中报告每股亏损 1.72 美元，显著低于预期</p>

<p>REGENXBIO (NASDAQ:RGNX - Get Free Report) had its price objective cut by stock analysts at Bank of America from $25.00 to $14.00 in a report released on Friday,Benzinga reports. The firm currently has a &#34;buy&#34; rating on the biotechnology company's stock. Bank of America's price objective suggests a potential upside of 139.93% from the company's current price.</p>
<div class="lb-trans"><p>REGENXBIO（纳斯达克代码：RGNX - 获取免费报告）在周五发布的报告中，摩根大通的股票分析师将其目标价格从 25.00 美元下调至 14.00 美元，Benzinga 报道。该公司目前对这家生物技术公司的股票给予 “买入” 评级。摩根大通的目标价格暗示该公司当前价格有 139.93% 的潜在上涨空间。</p>
</div><p>Several other brokerages have also issued reports on RGNX. Chardan Capital cut their target price on shares of REGENXBIO from $52.00 to $50.00 and set a &#34;buy&#34; rating for the company in a research report on Tuesday, February 10th. Robert W. Baird set a $27.00 price target on shares of REGENXBIO in a research note on Tuesday, February 10th. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of REGENXBIO in a research note on Thursday, January 22nd. Wall Street Zen downgraded shares of REGENXBIO from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Saturday, January 31st. Finally, Morgan Stanley set a $16.00 price target on shares of REGENXBIO in a research note on Friday. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, REGENXBIO has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $23.91.</p>
<div class="lb-trans"><p>其他几家券商也对 RGNX 发布了报告。Chardan Capital 在 2 月 10 日的研究报告中将 REGENXBIO 的目标价格从 52.00 美元下调至 50.00 美元，并给予该公司 “买入” 评级。Robert W. Baird 在 2 月 10 日的研究报告中设定了 REGENXBIO 的目标价格为 27.00 美元。Weiss Ratings 在 1 月 22 日的研究报告中重新发布了对 REGENXBIO 的 “卖出（d-）” 评级。Wall Street Zen 在 1 月 31 日的研究报告中将 REGENXBIO 的评级从 “持有” 下调至 “卖出”。最后，摩根士丹利在周五的研究报告中设定了 REGENXBIO 的目标价格为 16.00 美元。九位分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，REGENXBIO 的平均评级为 “适度买入”，共识目标价格为 23.91 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on REGENXBIO</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 REGENXBIO 的最新股票分析</strong></p>
</div><h2>REGENXBIO Stock Down 6.5%</h2>
<div class="lb-trans"><h2>REGENXBIO 股票下跌 6.5%</h2>
</div><p>NASDAQ:RGNX traded down $0.41 during midday trading on Friday, hitting $5.84. The company had a trading volume of 2,810,619 shares, compared to its average volume of 1,031,145. REGENXBIO has a 52-week low of $5.79 and a 52-week high of $16.19. The stock's fifty day moving average price is $8.92 and its 200-day moving average price is $11.03. The company has a market capitalization of $301.20 million, a PE ratio of -1.55 and a beta of 1.12.</p>
<div class="lb-trans"><p>在周五的午盘交易中，纳斯达克：RGNX 下跌 0.41 美元，报 5.84 美元。该公司的交易量为 2,810,619 股，而其平均交易量为 1,031,145 股。REGENXBIO 的 52 周低点为 5.79 美元，52 周高点为 16.19 美元。该股票的 50 日移动平均价格为 8.92 美元，200 日移动平均价格为 11.03 美元。该公司的市值为 3.012 亿美金，市盈率为-1.55，贝塔值为 1.12。</p>
</div><p>REGENXBIO (NASDAQ:RGNX - Get Free Report) last announced its earnings results on Thursday, May 14th. The biotechnology company reported ($1.72) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($1.82). REGENXBIO had a negative return on equity of 103.12% and a negative net margin of 113.75%.The company had revenue of $6.39 million during the quarter, compared to analysts' expectations of $25.84 million. As a group, research analysts forecast that REGENXBIO will post -2.88 earnings per share for the current year.</p>
<div class="lb-trans"><p>REGENXBIO（纳斯达克代码：RGNX - 获取免费报告）最后一次公布财报是在 5 月 14 日，生物技术公司报告每股收益（EPS）为-1.72 美元，低于市场共识预期的 0.10 美元，差距为-1.82 美元。REGENXBIO 的股本回报率为-103.12%，净利润率为-113.75%。该公司在本季度的收入为 639 万美元，而分析师的预期为 2584 万美元。作为一个整体，研究分析师预测 REGENXBIO 在本年度的每股收益将为-2.88 美元。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other news, insider Steve Pakola sold 15,309 shares of the company's stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $11.02, for a total transaction of $168,705.18. Following the completion of the transaction, the insider directly owned 232,617 shares of the company's stock, valued at approximately $2,563,439.34. This represents a 6.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 14.22% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他新闻中，内部人士 Steve Pakola 在 5 月 11 日的交易中出售了 15,309 股公司的股票。股票以平均价格 11.02 美元出售，总交易额为 168,705.18 美元。交易完成后，该内部人士直接持有 232,617 股公司的股票，价值约为 2,563,439.34 美元。这代表了他们持股比例的 6.17% 的减少。该出售在向 SEC 的法律文件中披露，文件可以通过此链接访问。14.22% 的股票由公司内部人士持有。</p>
</div><h2>Hedge Funds Weigh In On REGENXBIO</h2>
<div class="lb-trans"><h2>对 REGENXBIO 的对冲基金看法</h2>
</div><p>Several hedge funds and other institutional investors have recently modified their holdings of RGNX. AQR Capital Management LLC raised its stake in shares of REGENXBIO by 2,247.7% during the first quarter. AQR Capital Management LLC now owns 620,595 shares of the biotechnology company's stock valued at $4,437,000 after acquiring an additional 594,161 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in shares of REGENXBIO by 64.5% during the fourth quarter. Assenagon Asset Management S.A. now owns 1,160,380 shares of the biotechnology company's stock valued at $16,709,000 after acquiring an additional 454,977 shares during the last quarter. Invenomic Capital Management LP bought a new position in shares of REGENXBIO during the third quarter valued at about $4,120,000. Integral Health Asset Management LLC raised its stake in shares of REGENXBIO by 57.1% during the third quarter. Integral Health Asset Management LLC now owns 1,100,000 shares of the biotechnology company's stock valued at $10,615,000 after acquiring an additional 400,000 shares during the last quarter. Finally, State Street Corp raised its stake in shares of REGENXBIO by 15.2% during the fourth quarter. State Street Corp now owns 2,286,736 shares of the biotechnology company's stock valued at $32,929,000 after acquiring an additional 301,858 shares during the last quarter. 88.08% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>最近几家对冲基金和其他机构投资者修改了对 RGNX 的持股。AQR Capital Management LLC 在第一季度将其在 REGENXBIO 的股份增加了 2,247.7%。AQR Capital Management LLC 现在拥有 620,595 股生物技术公司的股票，价值 4,437,000 美元，此前在上个季度增持了 594,161 股。Assenagon Asset Management S.A.在第四季度将其在 REGENXBIO 的股份增加了 64.5%。Assenagon Asset Management S.A.现在拥有 1,160,380 股生物技术公司的股票，价值 16,709,000 美元，此前在上个季度增持了 454,977 股。Invenomic Capital Management LP 在第三季度购买了 REGENXBIO 的新头寸，价值约为 4,120,000 美元。Integral Health Asset Management LLC 在第三季度将其在 REGENXBIO 的股份增加了 57.1%。Integral Health Asset Management LLC 现在拥有 1,100,000 股生物技术公司的股票，价值 10,615,000 美元，此前在上个季度增持了 400,000 股。最后，State Street Corp 在第四季度将其在 REGENXBIO 的股份增加了 15.2%。State Street Corp 现在拥有 2,286,736 股生物技术公司的股票，价值 32,929,000 美元，此前在上个季度增持了 301,858 股。88.08% 的股票由机构投资者持有。</p>
</div><h2>REGENXBIO News Roundup</h2>
<div class="lb-trans"><h2>REGENXBIO 新闻汇总</h2>
</div><p>Here are the key news stories impacting REGENXBIO this week:</p>
<div class="lb-trans"><p>以下是本周影响 REGENXBIO 的主要新闻故事：</p>
</div><ul>
<li>Positive Sentiment: REGENXBIO reported positive topline results from its pivotal AFFINITY DUCHENNE study of RGX-202, saying the primary endpoint was met with high statistical significance and that microdystrophin expression correlated with functional improvement, which supports the program’s development path and potential accelerated approval. Article Title</li>
<li>Positive Sentiment: Management also highlighted additional pipeline catalysts, including progress for ABBV-RGX-314 in diabetic retinopathy, expected dosing in Q2, and other late-stage readouts later in 2026, which could create future upside if execution remains on track. Article Title</li>
<li>Neutral Sentiment: The company’s earnings call and related coverage focused on the clinical update and broader pipeline strategy, with investors parsing whether the new trial data can translate into a commercial opportunity. Article Title</li>
<li>Negative Sentiment: Q1 results were much worse than expected: REGENXBIO reported a larger-than-expected loss of $1.72 per share and revenue of $6.39 million versus consensus near $25.84 million, reinforcing concerns about the company’s financial runway and ongoing losses. Article Title</li>
<li>Negative Sentiment: Market commentary also pointed to cash concerns and the scale of the quarterly loss as reasons the stock sold off, suggesting the encouraging Duchenne data was not enough to offset balance-sheet worries. Article Title</li>
<li>Negative Sentiment: An insider sale by Steve Pakola added a small amount of negative sentiment, though this is less important than the trial and earnings news. Article Title</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：REGENXBIO 报告了其关键的 AFFINITY DUCHENNE 研究 RGX-202 的积极顶线结果，称主要终点以高统计显著性达成，且微型肌营养不良蛋白表达与功能改善相关，这支持了该项目的发展路径和潜在的加速审批。文章标题</li>
<li>积极情绪：管理层还强调了其他管道催化剂，包括 ABBV-RGX-314 在糖尿病视网膜病变方面的进展，预计将在第二季度进行给药，以及其他晚期结果将在 2026 年晚些时候公布，如果执行保持在轨道上，可能会创造未来的上行空间。文章标题</li>
<li>中性情绪：公司的财报电话会议及相关报道集中在临床更新和更广泛的管道战略上，投资者在分析新的试验数据是否能转化为商业机会。文章标题</li>
<li>消极情绪：第一季度的结果远低于预期：REGENXBIO 报告每股损失高达 1.72 美元，收入为 639 万美元，而共识接近 2584 万美元，这加剧了对公司财务持续性和持续亏损的担忧。文章标题</li>
<li>消极情绪：市场评论还指出现金担忧和季度亏损规模是导致股票下跌的原因，表明令人鼓舞的杜氏肌营养不良数据不足以抵消资产负债表的担忧。文章标题</li>
<li>消极情绪：Steve Pakola 的内部出售增加了一小部分消极情绪，尽管这比试验和财报消息的重要性要低。文章标题</li>
</ul>
</div><h2>About REGENXBIO</h2>
<div class="lb-trans"><h2>关于 REGENXBIO</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO's pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.</p>
<div class="lb-trans"><p>REGENXBIO Inc 是一家临床阶段的生物技术公司，专注于利用其专有的 NAV® AAV（腺病毒相关病毒）平台开发基因疗法。该公司设计了下一代 AAV 载体，旨在将功能基因传递到目标细胞，旨在解决一系列罕见遗传疾病以及眼科、代谢和神经系统疾病。REGENXBIO 的管道中有多个产品候选者处于不同的临床前和临床开发阶段，包括用于湿性年龄相关性黄斑变性（AMD）的 RGX-314、用于粘多糖贮积症 II 型（亨特综合症）的 RGX-121 以及用于其他罕见溶酶体贮积疾病的 RGX-121。</p>
</div><p>In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.</p>
<div class="lb-trans"><p>除了内部资助的项目外，REGENXBIO 还与主要生物制药公司建立了合作伙伴关系，以推进其 NAV 技术。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than REGENXBIO</li>
<li>Viking Sails to All-Time Highs—Fundamentals Signal More to Come</li>
<li>Datavalut Gains Traction: 5 Reasons to Sell Now</li>
<li>TMC Stock: Why This Pre-Revenue Miner Is Worth Watching</li>
<li>The Power Grid Is Dying—Is It Time to Buy Its Replacement?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 REGENXBIO</li>
<li>Viking 股价创历史新高——基本面信号显示未来还有更多</li>
<li>Datavalut 获得关注：现在卖出的五个理由</li>
<li>TMC 股票：为什么这家未盈利的矿业公司值得关注</li>
<li>电网正在衰退——是时候购买其替代品了吗？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkdOWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=RGNX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in REGENXBIO Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 REGENXBIO 吗？</h2>
</div><p>Before you consider REGENXBIO, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 REGENXBIO 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and REGENXBIO wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 REGENXBIO 并不在名单上。</p>
</div><p>While REGENXBIO currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 REGENXBIO 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Bank of America Has Lowered Expectations for REGENXBIO (NASDAQ:RGNX) Stock Price

Market Beat

Regenxbio

动态生物技术与基因组 ETF - Invesco

标普生物技术 ETF - SPDR

医药突破 ETF - ALPS

2 倍做多纳斯达克生物技术 ETF - ProShares

标普生物技术 3 倍做空 - Direxion

生物科技 ETF - VanEck Vectors

纳斯达克生物科技指数 ETF - iShares Nasdaq

Invesco Nasdaq Biotechnology ETF

美国银行

摩根士丹利

道富银行

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

State Street® US Equity Premium Inc ETF

美国银行调低了对 REGENXBIO（纳斯达克代码：RGNX）股票价格的预期